A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to Evaluate Potential Next-Day Residual Effects of a Single Evening Dose of 3mg Eszopiclone and 7.5mg Zopiclone in Healthy Adult Subjects
Phase of Trial: Phase III
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Eszopiclone (Primary) ; Zopiclone
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 24 Aug 2012 Results published in the Journal of Clinical Psychopharmacology.
- 08 Jan 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2008 New trial record.